On March 31, 2026, Galapagos NV announced a binding agreement with Gilead to advance a T Cell Engager Program aimed at treating autoimmune diseases. This is a significant development for the company.
AI Assistant
GALAPAGOS NV
2026
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.